Category: Portfolio News
Emporos and InterLink AI Partner, develop only POS-Integrated lighted will-call solution
Emporos, the industry’s leading Pharmacy Commerce System including Point of Sale (POS), and InterLink AI, creator of scripClip, a state-of-the-art, lighted pharmacy will-call system, are delighted to announce they have entered a strategic partnership. Pharmacies now have access to a POS-integrated lighted will-call solution for streamlined prescription will-call, checkout, and
Read More
Phase Four partners with Redwire to expand space propulsion offerings and deliver Hall Effect Thrusters
Phase Four, a leading provider of next generation electric propulsion solutions for satellites, proudly announces the signing of a strategic cooperation agreement with Redwire Space (Redwire). This partnership aims to build and deliver Hall Effect Thrusters (HETs) to both government and commercial markets, enhancing the company's capabilities and expanding our
Read More
Ventyx Biosciences announces positive preclinical data for CNS-penetrant NLRP3 inhibitor VTX3232 demonstrating reversal of obesity and improvements in cardiometabolic and inflammatory markers
Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced positive preclinical data for its CNS-penetrant NLRP3 inhibitor VTX3232 in murine diet-induced obesity models. “We are excited by these
Read More
Resolve Therapeutics publishes results of RSLV-132 Phase 2 long COVID study
Resolve Therapeutics, a mid-stage clinical development company pioneering transformative therapies for autoimmune and post-viral illnesses, has announced the publication of its Phase 2 long COVID results in Clinical Infectious Diseases. The publication entitled “Assessment of the Impact of RNase in Patients with Severe Fatigue Related to Post-Acute Sequelae of SARS-CoV-2
Read More
Finally, Graphene electronic devices available for all
Paragraf, the world’s only mass producer of graphene electronics using transfer-free graphene grown with conventional semiconductor processes, has opened a new online store to enable global access to its unique Graphene-based Field Effect Transistor (“GFET”). GFETs have a wide range of uses in the development of industry, medical, and chemical
Read MoreDARPA awards Phase Four $14.9M contract to develop Air Breathing Electric Propulsion for Very Low Earth Orbit operations
Phase Four, a leading provider of next generation electric propulsion (EP) solutions for satellites, has been awarded a $14.9M contract by the Defense Advanced Research Projects Agency (DARPA) to deliver an "air-breathing" EP system to enable extended satellite operations in Very Low Earth Orbit (VLEO), at altitudes as low as
Read More
Achronix FPGAs add support for Bluespec’s Linux-capable RISC-V Soft Processors to enable scalable processing
Achronix Semiconductor Corporation, a leader in high-performance FPGAs and embedded FPGA (eFPGA) IP, and Bluespec, Inc., an industry leader in RISC-V tools and silicon IP, has announced a family of Linux-capable RISC-V soft processors that are available for the Achronix Speedster®7t FPGA family. Marking an industry first, Bluespec’s RISC-V processors
Read MoreVentyx Biosciences reports clinical data for its NLRP3 inhibitor portfolio and provides pipeline updates at virtual investor event
Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, have provided clinical and pipeline updates during its virtual investor event. “We are excited to announce clinical updates from our novel
Read More
NorthSea Therapeutics initiates Phase 2A trial of Orziloben (NST-6179) in Intestinal Failure-Associated Liver Disease (IFALD)
NorthSea Therapeutics B.V. (‘NST’, or the ‘Company’), a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis (NASH) and other liver-associated metabolic diseases, has announced the dosing of the first patient in its Phase 2a clinical trial of Orziloben (NST-6179) in intestinal failure-associated liver disease (IFALD),
Read MoreResolve Therapeutics announces publication of Lupus clinical trial results
Resolve Therapeutics, a mid-stage clinical development biotechnology company pioneering first-in-class therapies for autoimmune diseases, has announced the publication of results from its phase 2a clinical trial of RSLV-132 in patients with Systemic Lupus Erythematosus (SLE) in Lupus Science & Medicine. The publication entitled "Evaluation of RNase therapy in systemic lupus
Read More
biomodal delivers the 6-base genome with a powerful new multiomic solution, duet evoC
Novel solution distinguishes 5‑methylcytosine (5mC) and 5‑hydroxymethylcytosine (5hmC) revealing unprecedented insights into current and future states of disease using one 5ng DNA sample biomodal, an omics-based life sciences technology and analytics company, has announced it’s delivering the 6-base genome to customers with the launch of duet multiomics solution evoC (duet
Read More
InvestEU in Belgium: EIB venture debt for bone therapy innovator Novadip
The European Investment Bank (EIB) and Novadip have signed a €18 million venture debt financing agreement supported by the European Union’s InvestEU initiative. The Belgian biotech company will use the funds to support clinical trials of NVD-003, an autologous bone product that provides one-time curative treatment to achieve long-term union
Read More